Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well alisertib with and without rituximab works in treating
patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Alisertib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal
antibodies, such as rituximab, can block cancer growth in different ways. Some block the
ability of cancer cells to grow and spread. Others find cancer cells and help kill them or
carry cancer-killing substances to them. Giving alisertib with and without rituximab may be
an effective treatment for B-cell non-Hodgkin lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Kristie Blum Ohio State University Comprehensive Cancer Center